Novartis

News
mycamine_pack_shot

Sandoz bulks up with Mycamine ahead of spin-off

With a separation from parent company Novartis now confirmed, Sandoz has moved to strengthen its revenue base with the acquisition of global rights to mainstay antifungal drug Mycamine from

News
Zolgensma

Free access to Zolgensma curbed, says Novartis

Novartis' programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company.

News
blood_cells1 1024x576

ASH roundup: late breakers take the stage

The final day of the ASH congress always includes a session on late-breaking studies, and this year was no exception, with presentations on Novartis' iptacopan in paroxysmal nocturnal haemo